Arcutis Biotherapeutics (ARQT) Retained Earnings (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Retained Earnings of -$1.1 billion for Q1 2026, down 820900.0% year-over-year from N/an in Q1 2025, and down 0.99% quarter-over-quarter from -$1.1 billion in Q4 2025.
Arcutis Biotherapeutics (ARQT) Retained Earnings (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$1.1 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 820900.0% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 820900.0% YoY), while the FY2025 annual figure was -$1.1 billion, down 1.44% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.1 billion, down from -$1.1 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.3 billion in Q3 2025, with the low at -$1.2 billion in Q2 2025.
- The 5-year median for Retained Earnings is -$1.1 million (2022), against an average of -$151.7 million.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings surged 246354.41% in 2025, then tumbled 820900.0% in 2026.
- Arcutis Biotherapeutics' Retained Earnings stood at -$1.1 million in 2022, then sank by 90314.73% to -$981.9 million in 2023, then retreated by 14.26% to -$1.1 billion in 2024, then dropped by 1.44% to -$1.1 billion in 2025, then retreated by 0.99% to -$1.1 billion in 2026.
- Business Quant data shows ARQT's Retained Earnings at -$1.1 billion in Q1 2026, -$1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 1.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Bn |
| Mar 31, 2026 | -1.15 Bn |
| Dec 31, 2025 | -1.14 Bn |
| Sep 30, 2025 | 1.31 Bn |
| Jun 30, 2025 | -1.16 Bn |
| Mar 31, 2025 | -140,000.00 |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | 533,000.00 |
| Jun 30, 2024 | -294,000.00 |
| Mar 31, 2024 | 1.24 Bn |
| Dec 31, 2023 | -981.90 Mn |
| Sep 30, 2023 | -915.60 Mn |
| Jun 30, 2023 | 951.65 Mn |
| Mar 31, 2023 | -799.90 Mn |
| Dec 31, 2022 | -1.09 Mn |
| Sep 30, 2022 | 920.11 Mn |
| Jun 30, 2022 | 736.67 Mn |
| Mar 31, 2022 | -472.63 Mn |
| Dec 31, 2021 | -408.31 Mn |
| Sep 30, 2021 | 699.99 Mn |